550 related items for PubMed ID: 20163990
1. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[Abstract] [Full Text] [Related]
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
[Abstract] [Full Text] [Related]
3. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J.
BMC Neurol; 2016 Jul 26; 16():117. PubMed ID: 27461166
[Abstract] [Full Text] [Related]
4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
Ann Neurol; 1996 Mar 26; 39(3):285-94. PubMed ID: 8602746
[Abstract] [Full Text] [Related]
5.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
6. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov 07; 352(9139):1491-7. PubMed ID: 9820296
[Abstract] [Full Text] [Related]
7.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
8.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
9. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G.
Mult Scler; 2018 May 07; 24(6):795-804. PubMed ID: 28485186
[Abstract] [Full Text] [Related]
10. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
Koch-Henriksen N, Sørensen PS.
Mult Scler; 2000 Jun 07; 6(3):172-5. PubMed ID: 10871828
[Abstract] [Full Text] [Related]
11. Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G, Frexalimab Phase 2 Trial Group.
N Engl J Med; 2024 Feb 15; 390(7):589-600. PubMed ID: 38354138
[Abstract] [Full Text] [Related]
12. ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH, Smilek DE, ACCLAIM Study Group.
Mult Scler; 2017 Apr 15; 23(5):686-695. PubMed ID: 27481207
[Abstract] [Full Text] [Related]
13. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE, Rose JW.
Neurotherapeutics; 2017 Oct 15; 14(4):842-858. PubMed ID: 28707278
[Abstract] [Full Text] [Related]
14. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R.
Proc Natl Acad Sci U S A; 2006 Apr 11; 103(15):5941-6. PubMed ID: 16585503
[Abstract] [Full Text] [Related]
15. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group.
Lancet; 2013 Jun 01; 381(9881):1905-15. PubMed ID: 23562090
[Abstract] [Full Text] [Related]
16. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C.
J Neurol Neurosurg Psychiatry; 1996 Sep 01; 61(3):251-8. PubMed ID: 8795595
[Abstract] [Full Text] [Related]
17. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW.
Neurology; 2000 Jan 11; 54(1):200-6. PubMed ID: 10636148
[Abstract] [Full Text] [Related]
18. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS, MESEMS investigators.
Lancet Neurol; 2021 Nov 11; 20(11):917-929. PubMed ID: 34687636
[Abstract] [Full Text] [Related]
19. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
Li DK, Paty DW.
Ann Neurol; 1999 Aug 11; 46(2):197-206. PubMed ID: 10443885
[Abstract] [Full Text] [Related]
20. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV.
Zh Nevrol Psikhiatr Im S S Korsakova; 2024 Aug 11; 124(4):86-96. PubMed ID: 38676683
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
